Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:JNJ
- CUSIP: 47816010
- Web: www.jnj.com
Capitalization:- Market Cap: $360.49 billion
- Outstanding Shares: 2,693,833,000
Average Prices:- 50 Day Moving Avg: $128.09
- 200 Day Moving Avg: $121.63
- 52 Week Range: $109.32 - $136.20
P/E:- Trailing P/E Ratio: 22.49
- Foreward P/E Ratio: 17.47
- P/E Growth: 2.95
Sales & Book Value:- Annual Revenue: $72.17 billion
- Price / Sales: 4.99
- Book Value: $26.10 per share
- Price / Book: 5.13
Dividend:- Annual Dividend: $3.36
- Dividend Yield: 2.5%
Profitability:- EBIDTA: $25.12 billion
- Net Margins: 22.87%
- Return on Equity: 26.50%
- Return on Assets: 13.38%
Debt:- Debt-to-Equity Ratio: 0.38%
- Current Ratio: 2.52%
- Quick Ratio: 2.17%
Misc:- Average Volume: 5.78 million shs.
- Beta: 0.81
- Short Ratio: 3.12
Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)
What is Johnson & Johnson's stock symbol?
Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."
How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?
Johnson & Johnson declared a quarterly dividend on Thursday, April 27th. Shareholders of record on Tuesday, May 30th will be paid a dividend of $0.84 per share on Tuesday, June 13th. This represents a $3.36 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date is Thursday, May 25th. This is a boost from Johnson & Johnson's previous quarterly dividend of $0.80. View Johnson & Johnson's Dividend History.
How were Johnson & Johnson's earnings last quarter?
Johnson & Johnson (NYSE:JNJ) announced its earnings results on Tuesday, April, 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.77 by $0.06. The business had revenue of $17.77 billion for the quarter, compared to the consensus estimate of $18.02 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. The firm's quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.68 earnings per share. View Johnson & Johnson's Earnings History.
When will Johnson & Johnson make its next earnings announcement?
Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?
17 brokerages have issued 12 month price targets for Johnson & Johnson's stock. Their forecasts range from $112.80 to $145.00. On average, they anticipate Johnson & Johnson's stock price to reach $130.99 in the next twelve months. View Analyst Ratings for Johnson & Johnson.
What are analysts saying about Johnson & Johnson stock?
Here are some recent quotes from research analysts about Johnson & Johnson stock:
- 1. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
- 2. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues. While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
- 3. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)
Who are some of Johnson & Johnson's key competitors?
Some companies that are related to Johnson & Johnson include Novartis AG (NVS), Pfizer (PFE), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), Abbott Laboratories (ABT), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX) and Patheon NV (PTHN).
Who are Johnson & Johnson's key executives?
Johnson & Johnson's management team includes the folowing people:
- Alex Gorsky, Chairman of the Board, Chief Executive Officer
- Dominic J. Caruso, Chief Financial Officer, Executive Vice President
- Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President
- Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer
- Michael H. Ullmann, Executive Vice President, General Counsel
- Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals
- Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer
- Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman
- Joseph Wolk, Vice President - Investor Relations
- Anne M. Mulcahy, Lead Independent Director
Who owns Johnson & Johnson stock?
Johnson & Johnson's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.28%), BlackRock Inc. (6.26%), State Street Corp (5.95%), State Farm Mutual Automobile Insurance Co. (1.40%), Bank of New York Mellon Corp (1.38%) and Wellington Management Group LLP (1.23%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.
Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?
Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Nordea Investment Management AB, Pioneer Investment Management Inc., Boston Partners, Parametric Portfolio Associates LLC, Wellington Management Group LLP, Morgan Stanley and Bank of New York Mellon Corp. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Paulus Stoffels and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.
Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?
Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Vanguard Group Inc., Renaissance Technologies LLC, Geode Capital Management LLC, Swiss National Bank, Alliancebernstein L.P. and Karp Capital Management Corp. View Insider Buying and Selling for Johnson & Johnson.
How do I buy Johnson & Johnson stock?
Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Johnson & Johnson's stock price today?
One share of Johnson & Johnson stock can currently be purchased for approximately $133.82.
MarketBeat Community Rating for Johnson & Johnson (NYSE JNJ)MarketBeat's community ratings are surveys of what our community members think about Johnson & Johnson and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 10 Hold Ratings, 7 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.41) |
| Consensus Price Target: | $130.99 (2.12% downside) |
Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/16/2017 | Jefferies Group LLC | Reiterated Rating | Hold | $140.00 | Medium |  |
| 6/15/2017 | Royal Bank Of Canada | Reiterated Rating | Buy | $128.00 | Medium | |
| 6/13/2017 | Cowen and Company | Reiterated Rating | Outperform | $143.00 | Low | |
| 6/2/2017 | BMO Capital Markets | Reiterated Rating | Buy | $132.00 | Low | |
| 5/21/2017 | BTIG Research | Reiterated Rating | Hold | | Low | |
| 5/19/2017 | Morgan Stanley | Reiterated Rating | Equal Weight | $130.00 -> $135.00 | Low | |
| 5/18/2017 | Stifel Nicolaus | Reiterated Rating | Hold -> Hold | $124.00 -> $128.00 | Low | |
| 5/15/2017 | J P Morgan Chase & Co | Upgrade | Neutral -> Overweight | $123.64 -> $140.00 | High | |
| 4/17/2017 | Barclays PLC | Reiterated Rating | Equal Weight | $125.00 -> $130.00 | Low | |
| 1/26/2017 | Wells Fargo & Company | Downgrade | Outperform -> Market Perform | $112.28 -> $112.80 | N/A | |
| 1/25/2017 | Goldman Sachs Group, Inc. (The) | Lower Price Target | Neutral | $120.00 -> $115.00 | N/A | |
| 12/20/2016 | Credit Suisse Group AG | Reiterated Rating | Hold | | N/A | |
| 11/28/2016 | Bank of America Corporation | Reiterated Rating | Hold | $126.00 | N/A | |
| 10/23/2016 | Societe Generale | Reiterated Rating | Hold | $116.00 | N/A | |
| 10/21/2016 | Argus | Reiterated Rating | Buy | $145.00 | N/A | |
| 9/11/2016 | Leerink Swann | Reiterated Rating | Buy | | N/A | |
| 8/19/2016 | Deutsche Bank AG | Reiterated Rating | Buy | $142.00 | N/A | |
| 5/20/2016 | Raymond James Financial, Inc. | Reiterated Rating | Outperform | $120.00 | N/A | |
| 5/20/2016 | Standpoint Research | Initiated Coverage | Sell | $94.00 | N/A | |
| 4/20/2016 | Piper Jaffray Companies | Boost Price Target | Neutral | $105.00 -> $106.00 | N/A | |
| 1/27/2016 | Independent Research GmbH | Set Price Target | Neutral | $108.00 | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Neutral | $95.00 | N/A | |
| 10/15/2015 | S&P Equity Research | Reiterated Rating | Buy | $120.00 | N/A | |
(Data available from 6/29/2015 forward)
Earnings History for Johnson & Johnson (NYSE:JNJ)Earnings History by Quarter for Johnson & Johnson (NYSE JNJ)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/18/2017 | | | | | | | | |
| 4/18/2017 | Q1 17 | $1.77 | $1.83 | $18.02 billion | $17.77 billion | View | N/A | |
| 1/24/2017 | Q416 | $1.56 | $1.58 | $18.28 billion | $18.10 billion | View | N/A | |
| 10/18/2016 | Q316 | $1.65 | $1.68 | $17.71 billion | $17.80 billion | View | Listen | |
| 7/19/2016 | Q216 | $1.68 | $1.74 | $17.98 billion | $18.50 billion | View | Listen | |
| 4/19/2016 | Q116 | $1.65 | $1.68 | $17.50 billion | $17.50 billion | View | Listen | |
| 1/26/2016 | Q415 | $1.42 | $1.44 | $17.88 billion | $17.80 billion | View | Listen | |
| 10/13/2015 | Q315 | $1.45 | $1.49 | $17.47 billion | $17.10 billion | View | Listen | |
| 7/14/2015 | Q215 | $1.69 | $1.71 | $17.76 billion | $17.80 billion | View | Listen | |
| 4/14/2015 | Q115 | $1.54 | $1.56 | $17.31 billion | $17.37 billion | View | Listen | |
| 1/20/2015 | Q414 | $1.25 | $1.27 | $18.59 billion | $18.30 billion | View | Listen | |
| 10/14/2014 | Q314 | $1.42 | $1.50 | $18.41 billion | $18.50 billion | View | Listen | |
| 7/15/2014 | Q214 | $1.54 | $1.66 | $18.86 billion | $19.50 billion | View | N/A | |
| 4/15/2014 | Q114 | $1.48 | $1.54 | $18.00 billion | $18.10 billion | View | N/A | |
| 1/21/2014 | Q413 | $1.20 | $1.24 | $17.95 billion | $18.40 billion | View | N/A | |
| 10/15/2013 | Q313 | $1.32 | $1.36 | $17.46 billion | $17.60 billion | View | N/A | |
| 7/16/2013 | Q2 2013 | $1.39 | $1.48 | $17.71 billion | $17.90 billion | View | N/A | |
| 4/16/2013 | Q1 2013 | $1.41 | $1.44 | $17.46 billion | $17.50 billion | View | N/A | |
| 1/22/2013 | Q4 2012 | $1.17 | $1.19 | $17.67 billion | $17.60 billion | View | N/A | |
| 10/16/2012 | | $1.21 | $1.25 | | | View | N/A | |
| 7/17/2012 | | $1.29 | $1.30 | | | View | N/A | |
| 4/17/2012 | | $1.34 | $1.37 | | | View | N/A | |
| 1/24/2012 | | $1.09 | $1.13 | | | View | N/A | |
| 10/18/2011 | | $1.21 | $1.24 | | | View | N/A | |
| 7/19/2011 | | $1.24 | $1.28 | | | View | N/A | |
| 4/19/2011 | | $1.26 | $1.35 | | | View | N/A | |
| 1/25/2011 | | $1.03 | $1.03 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Johnson & Johnson (NYSE:JNJ)2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.79
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $1.71 | $1.77 | $1.74 |
| Q2 2017 | 1 | $1.86 | $1.86 | $1.86 |
| Q3 2017 | 1 | $1.80 | $1.80 | $1.80 |
| Q4 2017 | 1 | $1.59 | $1.59 | $1.59 |
| Q1 2018 | 1 | $1.98 | $1.98 | $1.98 |
| Q2 2018 | 1 | $2.04 | $2.04 | $2.04 |
| Q3 2018 | 1 | $1.99 | $1.99 | $1.99 |
| Q4 2018 | 1 | $1.78 | $1.78 | $1.78 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Johnson & Johnson (NYSE:JNJ)| Most Recent Dividend: | 6/13/2017 |
| Annual Dividend: | $3.36 |
| Dividend Yield: | 2.51% |
| Dividend Growth: | 6.70% (3 Year Average) |
| Payout Ratio: | 56.47% (Trailing 12 Months of Earnings)
47.32% (Based on This Year's Estimates)
43.86% (Based on Next Year's Estimates)
|
| Track Record: | 54 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Johnson & Johnson (NYSE JNJ)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 4/27/2017 | quarterly | $0.84 | 2.72% | 5/25/2017 | 5/30/2017 | 6/13/2017 |
| 1/3/2017 | quarterly | $0.80 | 2.77% | 2/24/2017 | 2/28/2017 | 3/14/2017 |
| 10/20/2016 | quarterly | $0.80 | | 11/18/2016 | 11/22/2016 | 12/6/2016 |
| 7/18/2016 | quarterly | $0.80 | | 8/19/2016 | 8/23/2016 | 9/6/2016 |
| 4/28/2016 | quarterly | $0.80 | | 5/20/2016 | 5/24/2016 | 6/7/2016 |
| 1/4/2016 | quarterly | $0.75 | | 2/19/2016 | 2/23/2016 | 3/8/2016 |
| 10/22/2015 | quarterly | $0.75 | | 11/20/2015 | 11/24/2015 | 12/8/2015 |
| 7/20/2015 | quarterly | $0.75 | | 8/21/2015 | 8/25/2015 | 9/8/2015 |
| 4/23/2015 | quarterly | $0.75 | 2.97% | 5/21/2015 | 5/26/2015 | 6/9/2015 |
| 1/5/2015 | quarterly | $0.70 | 2.71% | 2/20/2015 | 2/24/2015 | 3/10/2015 |
| 10/16/2014 | quarterly | $0.70 | 2.89% | 11/21/2014 | 11/25/2014 | 12/9/2014 |
| 7/21/2014 | quarterly | $0.70 | 2.73% | 8/22/2014 | 8/26/2014 | 9/9/2014 |
| 4/24/2014 | quarterly | $0.70 | 2.81% | 5/22/2014 | 5/27/2014 | 6/10/2014 |
| 1/2/2014 | quarterly | $0.66 | 2.87% | 2/21/2014 | 2/25/2014 | 3/11/2014 |
| 10/17/2013 | quarterly | $0.66 | 2.88% | 11/22/2013 | 11/26/2013 | 12/10/2013 |
| 7/15/2013 | quarterly | $0.66 | 2.92% | 8/23/2013 | 8/27/2013 | 9/10/2013 |
| 4/25/2013 | quarterly | $0.66 | 3.1% | 5/23/2013 | 5/28/2013 | 6/11/2013 |
| 1/2/2013 | quarterly | $0.61 | 3.45% | 2/22/2013 | 2/26/2013 | 3/12/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 66.03%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 2/15/2017 | Paulus Stoffels | VP | Sell | 22,000 | $117.29 | $2,580,380.00 | |
| 10/21/2016 | Charles Prince | Director | Buy | 875 | $114.11 | $99,846.25 | |
| 7/26/2016 | Dominic J Caruso | VP | Sell | 41,146 | $125.01 | $5,143,661.46 | |
| 7/22/2016 | Ronald A Kapusta | CAO | Sell | 2,935 | $125.01 | $366,904.35 | |
| 6/7/2016 | Gary J Pruden | VP | Sell | 9,735 | $116.03 | $1,129,552.05 | |
| 6/7/2016 | Ronald A Kapusta | CAO | Sell | 3,000 | $115.79 | $347,370.00 | |
| 5/10/2016 | Ronald A Kapusta | CAO | Sell | 3,957 | $114.77 | $454,144.89 | |
| 2/17/2016 | Paulus Stoffels | insider | Sell | 125,000 | $102.43 | $12,803,750.00 | |
| 2/3/2016 | Peter Fasolo | VP | Sell | 151,385 | $104.12 | $15,762,206.20 | |
| 10/23/2015 | Ronald A. Kapusta | CAO | Sell | 6,239 | $99.68 | $621,903.52 | |
| 6/2/2015 | Charles Prince | Director | Buy | 2,500 | $99.22 | $248,050.00 | |
| 4/28/2015 | Paulus Stoffels | Insider | Sell | 187,250 | $100.73 | $18,861,692.50 | |
| 9/10/2014 | James Cullen | Director | Sell | 2,446 | $104.12 | $254,677.52 | |
| 5/5/2014 | Stephen Cosgrove | Insider | Sell | 22,000 | $100.05 | $2,201,100.00 | |
| 3/14/2014 | Peter Fasolo | VP | Sell | 6,824 | $93.15 | $635,655.60 | |
| 8/14/2013 | Stephen Cosgrove | Insider | Sell | 17,200 | $91.39 | $1,571,908.00 | |
| 8/5/2013 | Michael Ullmann | VP | Sell | 16,140 | $93.68 | $1,511,995.20 | |
| 7/25/2013 | Paulus Stoffels | Insider | Sell | 45,440 | $92.40 | $4,198,656.00 | |
| 7/18/2013 | Dominic J Caruso | CFO | Sell | 30,000 | $90.31 | $2,709,300.00 | |
| 11/12/2012 | James Cullen | Director | Sell | 13,900 | $69.70 | $968,830.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
| Source: |
|
| Date | Headline |
|---|
 | Pfizer’s Valuation as of June 22, 2017
finance.yahoo.com - June 27 at 6:15 PM |
| J&J CEO Gorsky Says U.S. Tax Reform Is Essential
finance.yahoo.com - June 26 at 7:56 PM |
| J&J CEO Gorsky Says Health Care Needs 10-20 Years of Work
finance.yahoo.com - June 26 at 7:56 PM |
| J&J CEO Gorsky Says Health Care Labor Market Is Tight
finance.yahoo.com - June 26 at 7:56 PM |
| This ‘classic’ Dow stock has come too far, too fast: Technician
finance.yahoo.com - June 26 at 7:56 PM |
 | Johnson & Johnson: The Better Activist Investor Bet
seekingalpha.com - June 25 at 6:51 PM |
| Trump’s adds NY Jets owner to diplomatic roster
finance.yahoo.com - June 25 at 6:51 PM |
| How Alphabet’s YouTube’s Ad Boycotters Fared
finance.yahoo.com - June 23 at 6:28 PM |
| A New ETF For Low Vol ETFs
finance.yahoo.com - June 23 at 6:28 PM |
 | Ex-DHS Secretary Jeh Johnson defends Obama handling of Russian meddling
abcnews.go.com - June 22 at 12:54 PM |
| Johnson & Johnson Releases 2016 Health for Humanity Report
finance.yahoo.com - June 22 at 12:54 PM |
| Johnson & Johnson seeks to have Missouri talc suits dismissed
finance.yahoo.com - June 22 at 12:54 PM |
| 3 Perfect Stocks for Retirees in Their 70s to Consider Buying
finance.yahoo.com - June 22 at 12:54 PM |
| Here's Why Geron (GERN) is a Good Stock to Invest in Now
finance.yahoo.com - June 22 at 12:53 PM |
| Markets Right Now: After early stumble, stocks drift higher
finance.yahoo.com - June 22 at 12:53 PM |
| UnitedHealth, HCA, Merck Rally As Senate TrumpCare Bill Pares Near-Term Cuts
finance.yahoo.com - June 22 at 12:53 PM |
 | Johnson & Johnson (JNJ) Expected to Post Quarterly Sales of $18.89 Billion
www.americanbankingnews.com - June 22 at 10:24 AM |
| Major Talc Case Against J&J Declared a Mistrial Following SCOTUS Ruling
finance.yahoo.com - June 21 at 3:49 PM |
| [$$] Missouri Files Its Own Suit Against Opioid-Painkiller Producers
finance.yahoo.com - June 21 at 3:49 PM |
| [$$] J&J Seeking Dismissal of Talc Lawsuits in Missouri
finance.yahoo.com - June 21 at 3:49 PM |
| Dems Roast Trump for Leaving Medicare Out of Drug Price Order
finance.yahoo.com - June 21 at 3:49 PM |
| Traders Buy Large Volume of Johnson & Johnson Put Options (JNJ)
www.americanbankingnews.com - June 21 at 7:14 AM |
 | US Supreme Court ruling threatens massive talc litigation against J&J - Reuters
www.reuters.com - June 21 at 5:01 AM |
| Mistrial declared in talc suit following Supreme Court ruling
finance.yahoo.com - June 20 at 6:58 PM |
| J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
finance.yahoo.com - June 20 at 6:58 PM |
| ETFs with exposure to Johnson & Johnson : June 20, 2017
finance.yahoo.com - June 20 at 6:58 PM |
| Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
finance.yahoo.com - June 20 at 6:58 PM |
| Five classic Dow stocks are surging
finance.yahoo.com - June 20 at 6:58 PM |
| A Short-Term Dip Is a Great Time to Consider Buying These Long-Term Stocks
finance.yahoo.com - June 20 at 6:58 PM |
| Why Pomalyst Could See Significant Revenue Growth in 2017
finance.yahoo.com - June 20 at 6:58 PM |
| Johnson & Johnson (JNJ) Expected to Announce Earnings of $1.79 Per Share
www.americanbankingnews.com - June 20 at 4:10 PM |
 | Supreme Court ruling results in talc lawsuit mistrial
marketbeat.com - June 19 at 5:48 PM |
| Just 10 stocks are having an incredible impact on the market this year
finance.yahoo.com - June 19 at 5:03 PM |
| Featured Company News - J&J Completes Actelion Acquisition
finance.yahoo.com - June 19 at 12:12 PM |
| J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
finance.yahoo.com - June 19 at 12:12 PM |
| AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
finance.yahoo.com - June 19 at 12:12 PM |
| Johnson & Johnson :JNJ-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 19 at 12:12 PM |
| 5 Reasons the Boring Parts of Johnson & Johnson's Business Should Generate Excitement
finance.yahoo.com - June 18 at 9:09 AM |
 | 5 Reasons the Boring Parts of Johnson & Johnson's Business Should Generate Excitement
www.fool.com - June 18 at 7:55 AM |
| Johnson & Johnson (JNJ) Upgraded at BidaskClub
www.americanbankingnews.com - June 17 at 5:26 PM |
| Johnson & Johnson's (JNJ) Management Presents at Goldman Sachs 38th Annual Global Healthcare Conference (Transcript)
seekingalpha.com - June 17 at 12:02 AM |
 | Johnson & Johnson (JNJ) Completes Acquisition of Actelion
www.streetinsider.com - June 16 at 6:58 PM |
| Featured Company News - Johnson & Johnson Announces Flu Drug Update; Pimodivir Succeeds Mid-Stage Trial
finance.yahoo.com - June 16 at 6:58 PM |
| Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
finance.yahoo.com - June 16 at 6:58 PM |
| Johnson & Johnson's (JNJ) Hold Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - June 16 at 8:10 AM |
| Johnson & Johnson Completes Acquisition of Actelion
www.streetinsider.com - June 16 at 6:57 AM |
 | Johnson & Johnson Closes Acquisition Of Actelion
www.nasdaq.com - June 16 at 6:57 AM |
| Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch
finance.yahoo.com - June 16 at 6:57 AM |
| Johnson & Johnson Announces Completion of Acquisition of Actelion
finance.yahoo.com - June 16 at 6:57 AM |
| Johnson & Johnson's (JNJ) "Buy" Rating Reaffirmed at Royal Bank Of Canada
www.americanbankingnews.com - June 15 at 9:26 PM |
Johnson & Johnson (JNJ) Chart for Thursday, June, 29, 2017
